This site is intended for Healthcare Professionals only.

NHS clinicians urge NICE to reverse decision declining romosozumab use for osteoporosis


Share post:

More than 100 NHS clinicians have urged the National Institute for Health and Care Excellence (NICE) to change its decision – declining recommendation of romosozumab, the first new osteoporosis medication for over a decade.

In a joint letter published on January 2, the clinicians warned of the consequences of barring access to the drug to those who suffer the bone-weakening disease.

The joint letter, led by the Royal Osteoporosis Society (ROS), raised concern over the scarcity of the drug pipeline for osteoporosis and lack of public funding for new research.

It quoted recent government research that showed the National Institute for Health Research (NIHR) invested less than £1 million in osteoporosis research in 2020-21, against the £4.6 billion per year cost to the NHS of fractures.

Craig Jones, chief executive of the Royal Osteoporosis Society said: “We’re calling on NICE and the applicant company to get back round the table and work with us to ensure equal access to this important new treatment.

“Osteoporosis clinicians fear that technical misunderstandings are leading to an unfair scenario where Scottish and Northern Irish patients have access to this life-changing medication, while people in England and Wales are left at the mercy of fractures.

“We hope both parties will work with us to find a way forward in the public interest”.

The drug is one of only two treatments licensed by MHRA which induces new bone formation.

The provisional decision from NICE is under consultation, pending a hearing scheduled for early in 2022.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...